Details for New Drug Application (NDA): 202323

NDA 202323 describes CARBIDOPA AND LEVODOPA, which is a drug marketed by Accord Hlthcare, Alembic, Apotex, Impax Labs, Kv Pharm, Mylan, Rubicon, Sciegen Pharms Inc, Sun Pharm Inds, Rising, Sun Pharm, Actavis Elizabeth, Ani Pharms, Apotex Inc, Aurobindo Pharma Ltd, Dr Reddys Labs Sa, SCS, Watson Labs, and Zydus Pharms, and is included in twenty-eight NDAs. It is available from thirty-one suppliers. Additional details are available on the CARBIDOPA AND LEVODOPA profile page.

The generic ingredient in CARBIDOPA AND LEVODOPA is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.

Summary for 202323

Tradename:	CARBIDOPA AND LEVODOPA
Applicant:	Accord Hlthcare
Ingredient:	carbidopa; levodopa
Patents:	0

Pharmacology for NDA: 202323

Suppliers and Packaging for NDA: 202323

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
CARBIDOPA AND LEVODOPA	carbidopa; levodopa	TABLET, EXTENDED RELEASE;ORAL	202323	ANDA	Accord Healthcare, Inc.	16729-078	16729-078-01	100 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-078-01)
CARBIDOPA AND LEVODOPA	carbidopa; levodopa	TABLET, EXTENDED RELEASE;ORAL	202323	ANDA	Accord Healthcare, Inc.	16729-078	16729-078-17	1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-078-17)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	25MG;100MG
Approval Date:	Feb 8, 2013	TE:	AB	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	50MG;200MG
Approval Date:	Feb 8, 2013	TE:	AB	RLD:	No

Complete Access Available with Subscription